Among the most overlooked contributors to premature death in people with serious psychiatric disorders is not the illness itself — it is the metabolic toll of the medications used to treat it. Antipsychotic-induced weight gain quietly drives obesity rates, insulin resistance, and type 2 diabetes in this population, shaving years off lives that are already medically underserved. A class of drugs originally designed for diabetes may be changing that calculus.
This review, published in the Canadian Journal of Psychiatry, synthesizes emerging evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) — including agents like semaglutide and liraglutide — specifically applied to antipsychotic-induced weight gain (AIWG) in people with severe and persistent mental illness (SPMI). Studies reviewed show meaningful reductions in both body weight and BMI among patients on antipsychotics who received GLP-1RAs, without evidence of psychiatric symptom worsening. Beyond weight, GLP-1RAs appear to improve lipid profiles, blood pressure, and glycemic control — a particularly relevant cluster of benefits given this population's outsized cardiometabolic risk. The review also surfaces preliminary signals around neuroprotective and mood-related effects, though these remain speculative at this stage.
The broader research context adds important texture. GLP-1RAs have accumulated robust cardiovascular outcome data in the general population, and their weight-loss efficacy is now well-established across multiple large randomized trials. However, individuals with SPMI have been systematically excluded from most of those landmark studies, meaning efficacy and safety data specific to this group remain thin. Traditional behavioral interventions — diet counseling, structured exercise — face obvious feasibility barriers in people managing psychosis, cognitive impairment, or significant social instability, making pharmacological solutions especially valuable here. The review is candid about access barriers: cost and restrictive formulary policies limit real-world uptake. As an analytic piece rather than a new clinical trial, its conclusions are hypothesis-generating rather than definitive. Long-term psychiatric safety data and cost-effectiveness modeling specific to this population remain needed before broad adoption can be confidently recommended.